非小细胞肺癌患者外周血造血干细胞相对计数和绝对计数检测的临床意义  

Relative and absolute counts of peripheral blood hematopoietic stem cells in patients with non-small cell lung cancer and their clinical significance

作　　者：赵芷洁若 刘云鹤[1] 刘阿庆[1] 夏颖 张冠 杨艳杰 于建春[1] ZHAO Zhi-jie-ruo;LIU Yun-he;LIU A-qing(First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300380,China)

机构地区：[1]天津中医药大学第一附属医院肿瘤科,天津300380

出　　处：《实用医药杂志》2021年第7期580-584,587,共6页Practical Journal of Medicine & Pharmacy

基　　金：天津市教委科研计划项目(2018KJ034)。

摘　　要：目的探讨非小细胞肺癌患者外周血造血干细胞CD34+相对计数和绝对计数水平及临床意义。方法选取2018年9月—2019年9月入住医院的100例非小细胞肺癌患者为观察组,52例同期于医院体检的正常人为对照组,分别采集外周血2 ml。流式细胞仪检测外周血造血干细胞CD34+细胞在非小细胞肺癌患者和正常人中的相对计数和绝对计数的差异,CD34+造血干细胞绝对计数与患者临床病理特征的相关性,采用Kaplan-Meier进一步分析CD34+造血干细胞相对计数和绝对计数与无进展生存期的关系。结果 NSCLC患者CD34+HSC相对计数(0.8%)和绝对计数(0.66 cells/μl)明显低于正常人CD34相对计数(2.36%)和绝对计数(1.66 cells/μl),差异具有统计学意义(P<0.001)。Ⅲ+Ⅳ期NSCLC患者CD34+HSC相对计数(0.50%)和绝对计数(0.535 cells/μl)明显低于Ⅰ+Ⅱ期NSCLC患者CD34相对计数(2.13%)和绝对计数(1.02 cells/μl),差异具有统计学意义(P<0.01)。单因素分析显示,CD34+HSC绝对计数水平与不同临床分期、是否存在淋巴结转移、是否出现远端转移以及CD4+T淋巴细胞绝对计数相关(P<0.05),而与年龄、性别、是否吸烟、病理类型、肿瘤大小、分化程度、CD3+T细胞、CD8+T细胞、B细胞和NK绝对计数无关。Kaplan-Meier生存分析显示,CD34+HSC相对计数≥0.80%、 HSC≥0.66 cells/μl患者的PFS显著延长(P<0.05)。结论外周血CD34+HSC水平与非小细胞肺癌密切相关,可以作为非小细胞肺癌预后的一个重要的指标。Objective To investigate the relative and absolute counts of CD34+in peripheral blood bone marrow hematopoietic stem cells and their clinical significance in patients with non-small cell lung cancer.Methods 100 patients with non-small cell lung cancer admitted to our hospital from September 2018 to September 2019 were selected as the observation group,and 52 normal subjects admitted to our hospital from September 2018 to September 2019 were selected as the control group.2ml peripheral blood was collected respectively.Flow cytometry was used to detect the differences in relative count and absolute count of peripheral blood hematopoietic stem cell CD34+cells in patients with non-small cell lung cancer and normal,absolute count CD34+hematopoietic stem cells and clinical pathologic features of patients.Kaplan-Meier was used to further analyze the relationship between the relative and absolute count of CD34+HSCS and progression-free survival.Results The relative count(0.8%)and absolute count(0.66cells/L)of CD34+HSC in NSCLC patients were significantly lower than those in normal controls(2.36%)and absolute count(1.66cells/L),with statistically significant differences(P<0.001).The relative count(0.50%)and absolute count(0.535cells/L)of CD34+HSC in stageⅢ+ⅣNSCLC patients were significantly lower than those in StageⅠ+ⅡNSCLC patients(2.13%)and absolute counts(1.02cells/L),with statistically significant differences(P<0.01).Showed that the absolute count of CD34+HSC was correlated with different clinical stages,the presence of lymph node metastasis,the presence of distal metastasis,and the absolute count of CD4+T lymphocytes(P<0.05).Age,sex,smoking or not,pathological type,tumor size,degree of differentiation,CD3+T cells,CD8+T cells,B cells,and absolute NK count were not correlated.Kaplan-Meier survival analysis showed that the PFS of patients with CD34+HSC≥0.80%and HSC≥0.66cells/L were significantly prolonged(P<0.05).Conclusion The level of CD34+HSC in peripheral blood is closely related to NSCLC and can be used

关 键 词：非小细胞肺癌 造血干细胞 CD34 预后 

分 类 号：R730.3[医药卫生—肿瘤] R655.3[医药卫生—临床医学]